CRGX · Insider Trading
CARGO Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CRGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-08-19 | John A Orwin | Director | D | −40,865 deriv. | — |
| 2025-08-19 | Jane Henderson | Director | D | −25,000 deriv. | — |
| 2025-08-19 | David Charles Lubner | Director | D | −25,000 deriv. | — |
| 2025-08-19 | Abraham Bassan | Director | D | −25,000 deriv. | — |
| 2025-08-19 | Kapil Dhingra | Director | D | −25,000 deriv. | — |
| 2025-08-19 | Reid M Huber | Director | D | −25,000 deriv. | — |
| 2025-08-19 | Anup Radhakrishnan | See Remarks | MIXED | −120,781 | −$528.90K |
| 2025-08-19 | Krishnan Viswanadhan | Director | D | −28,173 deriv. | — |
| 2025-07-03 | Anup Radhakrishnan | See Remarks | Sell | −1,632 | −$6.82K |
| 2025-06-23 | Krishnan Viswanadhan | Director | A | +25,000 deriv. | — |
| 2025-06-20 | Kapil Dhingra | Director | A | +25,000 deriv. | — |
| 2025-06-20 | John A Orwin | Director | A | +25,000 deriv. | — |
| 2025-06-20 | Abraham Bassan | Director | A | +25,000 deriv. | — |
| 2025-06-20 | Reid M Huber | Director | A | +25,000 deriv. | — |
| 2025-06-20 | Jane Henderson | Director | A | +25,000 deriv. | — |
| 2025-06-20 | David Charles Lubner | Director | A | +25,000 deriv. | — |
| 2025-05-16 | Anup Radhakrishnan | See Remarks | Sell | −27,404 | −$105.27K |
| 2025-05-14 | Anup Radhakrishnan | See Remarks | A | +72,500 | — |
| 2025-04-08 | Anup Radhakrishnan | See Remarks | Sell | −1,629 | −$6.52K |
| 2025-03-18 | Ginna Laport | Chief Medical Officer | A | +50,000 | — |
| 2025-03-18 | Gina Chapman | President & CEO | A | +200,000 | — |
| 2025-03-18 | Anup Radhakrishnan | See Remarks | A | +72,500 | — |
| 2025-03-18 | Shishir Gadam | Chief Technical Officer | A | +60,000 | — |
| 2024-11-15 | Anup Radhakrishnan | See Remarks | A | +40,000 deriv. | — |
| 2024-09-20 | Anup Radhakrishnan | Chief Financial Officer | MIXED | — | −$32.40K |
| 2024-09-20 | Gina Chapman | President & CEO | MIXED | — | −$203.22K |
| 2024-06-06 | David Charles Lubner | Director | A | +23,742 deriv. | — |
| 2024-06-06 | Krishnan Viswanadhan | Director | A | +23,742 deriv. | — |
| 2024-06-06 | Kapil Dhingra | Director | A | +11,871 deriv. | — |
| 2024-06-06 | Abraham Bassan | Director | A | +23,742 deriv. | — |
| 2024-06-06 | Reid M Huber | Director | A | +23,742 deriv. | — |
| 2024-06-06 | John A Orwin | Director | A | +23,742 deriv. | — |
| 2024-06-06 | Jane Henderson | Director | A | +59,187 deriv. | — |
| 2024-06-03 | Srinivas Akkaraju | 10%+ Owner | Buy | +882,000 | +$14.99M |
| 2024-04-17 | Kapil Dhingra | Director | A | +49,265 deriv. | — |
| 2024-03-04 | Anup Radhakrishnan | Chief Financial Officer | A | +130,000 deriv. | — |
| 2024-03-04 | Gina Chapman | President & CEO | A | +400,000 deriv. | — |
| 2024-03-04 | Shishir Gadam | Chief Technical Officer | A | +100,000 deriv. | — |
| 2024-03-04 | Ginna Laport | Chief Medical Officer | A | +100,000 deriv. | — |
| 2024-01-16 | Roderick Wong | 10%+ Owner | J | −3,684,998 | — |
| 2023-11-16 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | +737,000 | — |
| 2023-11-16 | Samsara BioCapital, L.P. | 10%+ Owner | MIXED | +12,143,967 | +$30.00M |
| 2023-11-14 | Joseph Edelman | — | MIXED | +12,984,672 | +$40.00M |
| 2023-11-14 | TRV GP V, LLC | 10%+ Owner | MIXED | +21,266,010 | +$120.00M |
| 2023-11-13 | David Charles Lubner | Director | A | +25,000 deriv. | — |
| 2023-11-13 | Krishnan Viswanadhan | Director | A | +25,000 deriv. | — |
| 2023-11-13 | Anup Radhakrishnan | Chief Financial Officer | A | +100,000 deriv. | — |
| 2023-11-13 | Abraham Bassan | Director | A | +25,000 deriv. | — |
| 2023-11-13 | Reid M Huber | Director | A | +25,000 deriv. | — |
| 2023-11-13 | John A Orwin | Director | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gina Chapman | President & CEO | 303,905 | $1.36M |
| Shishir Gadam | Chief Technical Officer | 89,480 | $399.98K |
| Anup Radhakrishnan | See Remarks | 63,436 | $283.56K |
| Ginna Laport | Chief Medical Officer | 50,000 | $223.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRGX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.